A warm welcome to the Renal Function Webinar, conducted on July 24, 2025, and proudly organized by ConfMeets. We are delighted to have you join us for this insightful session dedicated to exploring advancements, challenges, and innovations in renal health.
Today, we bring together esteemed experts, researchers, and healthcare professionals to share their knowledge and expertise. This webinar aims to foster meaningful discussions, enhance understanding, and contribute to improved patient care and clinical practices.
The Conference on Renal Function is a dedicated platform for medical professionals, researchers, and healthcare experts to discuss the latest advancements in nephrology and kidney disease management. The event aims to foster collaboration, share groundbreaking research, and explore innovative treatments that enhance patient care. With kidney diseases becoming increasingly prevalent worldwide, this conference provides an essential forum for addressing pressing challenges and solutions in renal health.
Renal function plays a crucial role in overall well-being, as the kidneys are responsible for filtering waste, regulating electrolytes, and maintaining fluid balance. This conference will delve into key topics such as chronic kidney disease (CKD), acute kidney injury (AKI), renal transplantation, and dialysis advancements. Experts will share insights on cutting-edge therapies, including regenerative medicine, artificial kidneys, and novel pharmacological approaches that are transforming the field of nephrology.
The global renal failure treatment market was valued at USD 112.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 8.3% from 2024 to 2030. A variety of factors contribute to this market's expansion, including the rising prevalence of chronic kidney disease (CKD), advancements in technology and treatment techniques, increased awareness and education about kidney health, and supportive government initiatives and regulations. Together, these elements drive market development, resulting in better patient outcomes and improved access to care. For instance, in July 2023, Boehringer Ingelheim and Eli Lilly and Company declared that the European Medicines Agency (EMA) approved Empagliflozin as the first SGLT2 inhibitor for treating CKD in adult patients.
The growing population of older adults is a vital factor contributing to the growth of the chronic kidney disease treatment market. Older adults are particularly vulnerable to developing and progressing chronic kidney disease, which raises the demand for innovative treatment options. The Centers for Disease Control and Prevention (CDC) indicates that CKD mainly affects individuals aged 65 and older (38.0%), followed by those aged 45 to 64 years (12.0%) and those aged 18 to 44 years (6.0%). This demographic shift is anticipated to further boost market growth.
Advancements in treatment technologies also play a crucial role. Innovations such as high-efficiency dialysis machines, portable artificial kidneys, and improved dialyzer membranes are transforming renal healthcare. Recent innovations include the launch of portable dialysis systems that enhance patient mobility and comfort. For example, in February 2024, Fresenius Medical Care